Senseonics (NYSEAMERICAN:SENS) posted its quarterly earnings results on Thursday. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01, Briefing.com reports. The business had revenue of $5.16 million during the quarter, compared to analysts’ expectations of $5.16 million. During the same period in the previous year, the company posted ($0.13) earnings per share. Senseonics’s revenue for the quarter was up 145.7% compared to the same quarter last year.
Shares of SENS stock traded down $0.39 during mid-day trading on Friday, hitting $3.58. 123,765 shares of the stock were exchanged, compared to its average volume of 1,521,011. Senseonics has a 52-week low of $2.41 and a 52-week high of $5.29.
Several research firms have recently issued reports on SENS. Dougherty & Co began coverage on shares of Senseonics in a research note on Friday, August 24th. They set a “buy” rating and a $6.00 target price on the stock. BTIG Research reissued a “buy” rating and set a $6.00 target price on shares of Senseonics in a research note on Thursday, August 9th. Six investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus target price of $6.00.
Senseonics Company Profile
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Featured Story: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.